ORCHARD THERAPEUTICS PLC-ADR (ORTX) Stock Analyst Ratings
USA - NASDAQ:ORTX - US68570P2002 - ADR
16.7 USD
+0.05 (+0.3%)
ChartMill assigns a Buy % Consensus number of 46% to ORTX. The Buy consensus is the weighted average rating of the current analysts ratings.
Analysts have set a mean price target forecast of 16.32. This target is -2.28% below the current price.
ORTX was analyzed by 7 analysts. The buy percentage consensus is at 46. So analysts seem to be rather neutral about ORTX.
In the previous month the buy percentage consensus was at a similar level.
ORTX was analyzed by 7 analysts. More opinions would make the average more meaningful.
Price Target & Forecast
| Date | Firm | Action | Rating |
|---|---|---|---|
| 2023-10-05 | Stifel | Downgrade | Buy -> Hold |
| 2023-08-09 | Oppenheimer | Reiterate | Outperform -> Outperform |
| 2023-06-27 | Cantor Fitzgerald | Reiterate | Overweight -> Overweight |
| 2023-06-13 | Oppenheimer | Maintains | Outperform -> Outperform |
| 2023-03-28 | Cantor Fitzgerald | Maintains | Overweight |
| 2022-05-13 | Barclays | Maintains | Overweight |
| 2021-11-16 | JP Morgan | Downgrade | Neutral -> Underweight |
| 2021-11-05 | Oppenheimer | Maintains | Outperform |
| 2021-08-18 | JP Morgan | Downgrade | Overweight -> Neutral |
ORCHARD THERAPEUTICS PLC-ADR / ORTX FAQ
What do analysts expect the price target to be for ORCHARD THERAPEUTICS PLC-ADR (ORTX)?
7 analysts have analysed ORTX and the average price target is 16.32 USD. This implies a price decrease of -2.28% is expected in the next year compared to the current price of 16.7.
How do analysts rate ORCHARD THERAPEUTICS PLC-ADR (ORTX)?
The consensus rating for ORCHARD THERAPEUTICS PLC-ADR (ORTX) is 45.7143 / 100 . This indicates that analysts generally have a neutral outlook on the stock.
Can you provide the analyst count for ORCHARD THERAPEUTICS PLC-ADR stock?
The number of analysts covering ORCHARD THERAPEUTICS PLC-ADR (ORTX) is 7.